China SXT Pharmaceuticals terminates over-allotment option on registered direct offering

China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) announced on October 21, 2026 that it had entered into a termination letter agreement with the purchasers in its registered direct offering that was announced on October 8, 2026. Under the agreement, the company and the purchasers terminated in full the additional purchase right set forth in Section 2.4 of the securities purchase agreement, which had permitted purchasers to elect, during the 30-day period following the closing of the offering, to buy up to an additional $12 million of Class A ordinary shares and/or pre-funded warrants on the same terms as the original offering.¹

The original offering involved 8,000,000 units, with each unit consisting of one Class A ordinary share or a pre-funded warrant in lieu of it, plus one ordinary warrant, priced at $1.50 per unit.¹

As a result of the termination, the purchasers no longer have any right, claim or entitlement to make an additional purchase under Section 2.4 of the securities purchase agreement.¹ All other provisions of the securities purchase agreement and related transaction documents remain unchanged and in full force and effect, and the termination does not affect the securities already issued in the offering.¹

The filing was signed by Co-Chief Executive Officers Feng Zhou and Simon Lim Sze Beng. China SXT Pharmaceuticals was founded in 2005 and is headquartered in Taizhou City, Jiangsu Province, China, where it focuses on research, development, manufacture, marketing and sales of traditional Chinese medicine pieces.¹